Your shopping cart is currently empty

LLC1, a derivative of amiloride, exhibits cytotoxicity against breast cancer cells, particularly those resistant to other treatments. The compound demonstrates varied IC50 values across several breast cancer cell lines, including 13 mM for MCF7, 12 mM for MCF7 MX-100, 25 mM for MCF7 TS, 26 mM for MCF7 TR-1, and 19 mM for MCF7 TR-5. LLC1 holds potential for research in cancer therapy.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | LLC1, a derivative of amiloride, exhibits cytotoxicity against breast cancer cells, particularly those resistant to other treatments. The compound demonstrates varied IC50 values across several breast cancer cell lines, including 13 mM for MCF7, 12 mM for MCF7 MX-100, 25 mM for MCF7 TS, 26 mM for MCF7 TR-1, and 19 mM for MCF7 TR-5. LLC1 holds potential for research in cancer therapy. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.